A Review Article on Helicobacter pylori Antibiotic Resistance Profile in Iran
Shirin Eyvazi
Faculty of Biotechnology, Rab-rashid Higher Education Institute, Tabriz, Iran and Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mojdeh Hakemi-Vala *
Department of Microbiology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
*Author to whom correspondence should be addressed.
Abstract
Now a day, antibiotic resistance is a global health threat which is considered as the major cause of treatment failures in bacterial infection. H. pylori (Helicobacter pylori) is a spiral-shaped gram negative bacterium that colonizes in gastric mucosa and is responsible for serious gastrointestinal diseases including peptic ulcers and gastric cancer. Appearance and increasing of antibiotic resistance in the recent years, mainly to metronidazole (in developing countries) and clarithromycin (in developed countries) have decreased the efficacy of H. pylori treatment regimens. The prevalence of H. pylori antibiotic resistance is not the same in all over the world and shows geographical variations. So, antibiotic treatment regimens should be administrating according to local antibiotic susceptibility pattern. Iran is a developing country in Middle East with the high prevalence of H. pylori infection about 80%. Many Iranian researchers from different provinces have investigated the susceptibility of H. pylori isolates to common antibiotics. So, the aim of this review paper was survey on the existence reports of Iranian authors to access an accurate antibiotic profile of H. pylori for efficient eradication therapy in the future.
Keywords: Helicobacter pylori, antibiotic resistance, metronidazole, clarithromycin, Iran